GB Sciences, Inc.
GB Sciences, Inc.
Your view on GBLX
Overview
What the company does, where it operates, and who runs it.
About GB Sciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Andrea Small-Howard
- Headquarters
- 3550 West Teco Avenue, Las Vegas, NV, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Andrea Small-Howard
- Headquarters
- 3550 West Teco Avenue, Las Vegas, NV, US
GB Sciences, Inc. engages in the research and development of plant-based medicines in North America and Europe. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market.
Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs.
The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for GB Sciences, Inc., and the rating behind it. GBLX last traded at $0.0003; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for GB Sciences, Inc.. Starting points for GB Sciences, Inc.: beta 9.86 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for GB Sciences, Inc.. GB Sciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for GB Sciences, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for GB Sciences, Inc.. GB Sciences, Inc. has reported as a listed company since 2008. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
GB Sciences, Inc. valued side by side against its closest peers. GB Sciences, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold GB Sciences, Inc., and how their positions are changing. At a $122,121 market value, institutional positions materially move GB Sciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by GB Sciences, Inc. executives and directors. Shares of GB Sciences, Inc. have traded between $0.0001 and $0.0085 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming GB Sciences, Inc.. GB Sciences, Inc. is a $122,121 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming GB Sciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for GB Sciences, Inc.. Coverage tracks GB Sciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.